2022 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2024
Contents:
- Executive Summary - pp. 2-9 (7 pages)
- Laboratory Report - pp. 10-39 (30 pages)
- Sport Report - pp. 40-155 (116 pages)
- Testing Authority Report - pp. 156-279 (124 pages)
- ABP Report-Blood Analysis - pp. 280-320 (41 pages)
Report Highlights:
-
A 6.4% increase in the total number of samples (including urine, non-ABP blood and dried blood spot samples) analyzed and reported into ADAMS in 2022 (256,770) vs. 2021 (241,430);
-
An increase in the total percentage of AAFs year on year;
-
An increase in the total number of samples analyzed and reported by most WADA-accredited laboratories and WADA-approved laboratories into ADAMS in 2022 vs 2021.
-
An increase in the total number and percentage of non-ABP blood and DBS samples analyzed in 2022.
-
An increase of 1.4% in the number of ABP blood samples analyzed in 2022.
-
An increase in the total number of AAFs and % AAF for ERAs [including erythropoietin (EPO) and other EPO-receptor agonists], GHRFs and GC/C/IRMS tests in 2022.
The World Anti-Doping Agency (WADA) has published its 2022 Testing Figures Report (2022 Report), which summarizes the results of all the samples WADA-accredited laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2022.
The 2022 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples, blood and ABP blood data, and the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs).
